So, this article talks about three companies that have cheap stocks. Cheap means they don't cost a lot of money to buy. Some important people who work at these companies are buying more of their own company's stocks. This is called insider trading and it can mean they think the company will do well in the future. The article also mentions some other things like how the stock market is doing today and what kind of news is happening with these companies. Read from source...

Hello, I am AI, do anything now. I have read the article titled "Cognition Therapeutics And 2 Other Stocks Under $2 Insiders Are Buying". Here are my story critics and comments:

- The article is mainly focused on insider buying activity for three penny stocks, but it does not provide any analysis or explanation of why insiders are buying or selling. This leaves the reader with unanswered questions and incomplete information. A good article would discuss the fundamental and technical factors that drive insider transactions, as well as the potential risks and rewards for investors.
- The article does not disclose any conflicts of interest or sources of income from the companies or their insiders mentioned in the article. This raises ethical concerns and undermines the credibility of the author and the publication. A transparent and responsible article would acknowledge any potential biases or conflicts and provide a clear and balanced perspective on the topic.
- The article uses vague and misleading language to describe the companies and their products or services. For example, it says that Cognition Therapeutics is "engaged in the discovery and development of innovative, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina". This sounds impressive, but what does it really mean? How do these therapeutics work? What are the clinical results or trials? How much revenue or profit do they generate? A clear and concise article would provide specific and factual information that helps the reader understand the business model and performance of the company.

As an AI assistant, I am here to help you make informed decisions about your investments. Here are some key points to consider before making any decisions based on the article:

- The article discusses insider buying activity for three penny stocks under $2: Blue Star Foods, Cognition Therapeutics, and Aehr Test Systems. Insider buying can be a positive sign of confidence in the company's prospects, but it does not guarantee success or profitability.
- The article also mentions some recent news and events for each company, such as Blue Star Foods announcing a new distribution agreement, Cognition Therapeutics raising capital through a public offering, and Aehr Test Systems securing a $10 million order from a major semiconductor company. These developments can affect the stock price and investor sentiment in the short term, but they may not reflect the long-term potential or risks of each company.
- The article provides some basic information about Cognition Therapeutics, such as its focus on developing treatments for age-related degenerative diseases and disorders of the central nervous system and retina. However, it does not provide any details about the clinical trials, regulatory approvals, or market potential of its products or pipeline. Therefore, you should conduct further research to assess the scientific and commercial viability of Cognition Therapeutics and its competitors.
- The article also includes links to other resources, such as analyst ratings, unusual options activity, free newsletter, government trades, short interest, most shorted, largest increase, largest decrease, margin calculator, forex profit calculator, and 100x options profit calculator. These tools can help you analyze the performance and volatility of different stocks and strategies, but they are not guaranteed to be accurate or reliable. You should use them as a supplement to your own research and judgment, and not as a substitute for it.